| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8969377 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Dec, 2029
(5 years from now) | |
| US8541448 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Aug, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9408840 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder |
Dec, 2029
(5 years from now) | |
| US9006281 | ARDELYX INC | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
May, 2030
(6 years from now) | |
Ibsrela is owned by Ardelyx Inc.
Ibsrela contains Tenapanor Hydrochloride.
Ibsrela has a total of 4 drug patents out of which 0 drug patents have expired.
Ibsrela was authorised for market use on 12 September, 2019.
Ibsrela is available in tablet;oral dosage forms.
Ibsrela can be used as method of treating irritable bowel syndrome with constipation by administering tenapanor.
Drug patent challenges can be filed against Ibsrela from 13 September, 2023.
The generics of Ibsrela are possible to be released after 01 August, 2033.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 12, 2024 |
Drugs and Companies using TENAPANOR HYDROCHLORIDE ingredient
NCE-1 date: 13 September, 2023
Market Authorisation Date: 12 September, 2019
Treatment: Method of treating irritable bowel syndrome with constipation by administering tenapanor
Dosage: TABLET;ORAL
IBSRELA family patents
